BACKGROUND: A validated tool to assess adherence with inhaled corticosteroids (ICS) could help physicians and researchers determine whether poor asthma control is due to poor adherence or severe intrinsic asthma. OBJECTIVE: To assess the performance of the Medication Adherence Report Scale for Asthma (MARS-A), a 10-item, self-reported measure of adherence with ICS. METHODS: We interviewed 318 asthmatic adults receiving care at 2 inner-city clinics. Self-reported adherence with ICS was measured by MARS-A at baseline and 1 and 3 months. ICS adherence was measured electronically in 53 patients. Electronic adherence was the percentage of days patients used ICS. Patients with a mean MARS-A score of 4.5 or higher or with electronic adherence of more than 70% were defined as good adherers. We assessed internal validity (Cronbach alpha, test-retest correlations), criterion validity (associations between self-reported adherence and electronic adherence), and construct validity (correlating self-reported adherence with ICS beliefs). RESULTS: The mean patient age was 47 years; 40% of patients were Hispanic, 40% were black, and 18% were white; 53% had prior asthma hospitalizations; and 70% had prior oral steroid use. Electronic substudy patients were similar to the rest of the cohort in age, sex, race, and asthma severity. MARS-A had good interitem correlation in English and Spanish (Cronbach alpha = 0.85 and 0.86, respectively) and good test-retest reliability (r = 0.65, P < .001). According to electronic measurements, patients used ICS 52% of days. Continuous MARS-A scores correlated with continuous electronic adherence (r = 0.42, P<.001), and dichotomized high self-reported adherence predicted high electronic adherence (odds ratio, 10.6; 95% confidence interval, 2.5-44.5; P < .001). Construct validity was good, with self-reported adherence higher in those saying daily ICS use was important and ICS were controller medications (P = .04). CONCLUSIONS: MARS-A demonstrated good psychometric performance as a self-reported measure of adherence with ICS among English- and Spanish-speaking, low-income, minority patients with asthma.
BACKGROUND: A validated tool to assess adherence with inhaled corticosteroids (ICS) could help physicians and researchers determine whether poor asthma control is due to poor adherence or severe intrinsic asthma. OBJECTIVE: To assess the performance of the Medication Adherence Report Scale for Asthma (MARS-A), a 10-item, self-reported measure of adherence with ICS. METHODS: We interviewed 318 asthmatic adults receiving care at 2 inner-city clinics. Self-reported adherence with ICS was measured by MARS-A at baseline and 1 and 3 months. ICS adherence was measured electronically in 53 patients. Electronic adherence was the percentage of days patients used ICS. Patients with a mean MARS-A score of 4.5 or higher or with electronic adherence of more than 70% were defined as good adherers. We assessed internal validity (Cronbach alpha, test-retest correlations), criterion validity (associations between self-reported adherence and electronic adherence), and construct validity (correlating self-reported adherence with ICS beliefs). RESULTS: The mean patient age was 47 years; 40% of patients were Hispanic, 40% were black, and 18% were white; 53% had prior asthma hospitalizations; and 70% had prior oral steroid use. Electronic substudy patients were similar to the rest of the cohort in age, sex, race, and asthma severity. MARS-A had good interitem correlation in English and Spanish (Cronbach alpha = 0.85 and 0.86, respectively) and good test-retest reliability (r = 0.65, P < .001). According to electronic measurements, patients used ICS 52% of days. Continuous MARS-A scores correlated with continuous electronic adherence (r = 0.42, P<.001), and dichotomized high self-reported adherence predicted high electronic adherence (odds ratio, 10.6; 95% confidence interval, 2.5-44.5; P < .001). Construct validity was good, with self-reported adherence higher in those saying daily ICS use was important and ICS were controller medications (P = .04). CONCLUSIONS: MARS-A demonstrated good psychometric performance as a self-reported measure of adherence with ICS among English- and Spanish-speaking, low-income, minority patients with asthma.
Authors: Dana Tiggelman; Monique O M van de Ven; Onno C P van Schayck; Rutger C M E Engels Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: David B Kantor; Molly C McDonald; Nicole Stenquist; Blake J Schultz; Craig D Smallwood; Kyle A Nelson; Wanda Phipatanakul; Joel N Hirschhorn Journal: Am J Respir Crit Care Med Date: 2016-12-15 Impact factor: 21.405
Authors: Alex D Federman; Michael S Wolf; Anastasia Sofianou; Melissa Martynenko; Rachel O'Connor; Ethan A Halm; Howard Leventhal; Juan P Wisnivesky Journal: J Am Geriatr Soc Date: 2014-04-29 Impact factor: 5.562
Authors: Jonathan M Feldman; Lynne Matte; Alejandro Interian; Paul M Lehrer; Shou-En Lu; Bari Scheckner; Dara M Steinberg; Tanya Oken; Anu Kotay; Sumita Sinha; Chang Shim Journal: Behav Res Ther Date: 2016-09-17
Authors: Taylor L Brooks; Howard Leventhal; Michael S Wolf; Rachel O'Conor; Jose Morillo; Melissa Martynenko; Juan P Wisnivesky; Alex D Federman Journal: J Gen Intern Med Date: 2014-08-05 Impact factor: 5.128
Authors: Alex D Federman; Michael Wolf; Anastasia Sofianou; Elizabeth A H Wilson; Melissa Martynenko; Ethan A Halm; Howard Leventhal; Juan P Wisnivesky Journal: Patient Educ Couns Date: 2013-03-21
Authors: Katherine Krauskopf; Alex D Federman; Minal S Kale; Keith M Sigel; Melissa Martynenko; Rachel O'Conor; Michael S Wolf; Howard Leventhal; Juan P Wisnivesky Journal: COPD Date: 2014-06-24 Impact factor: 2.409